Bringing the Oncology Community Together
FDA Approves Olaparib for Advanced Ovarian Cancer
The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.
Read More >>
The New BRCA1/2 Landscape
Ovarian Suppression Emerges as “Practice-Changing” Option for Younger, Premenopausal Breast Cancer Patients
How Is Treatment Changing for Patients With Cervical Cancer? Three Experts Weigh In
PARP Inhibitors for Breast and Ovarian Cancers
FDA Approves Bevacizumab for Recurrent Ovarian Cancer
New Research Focuses on Personalized Treatments in Ovarian Cancer
View More >>
- A Network of Your Peers
View more >>
Timing of Oophorectomy in Ovarian Cancer
Dr. Francis on the Benefits of Ovarian Suppression for Younger Women
Prophylactic Oophorectomy for Reducing Ovarian Cancer Risk
Most Popular Right Now
Tweets by @OncLive
Support and Assistance for Patients with Cancer
Useful information on supporting and assisting patients with cancer.
Community Practice Connections: 9th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies
CME activity worth 1.0 CME credits led by James Tate Thigpen, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.